Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1963 5
1964 8
1966 3
1967 1
1972 1
1976 2
1977 1
1978 1
1979 3
1980 2
1981 8
1982 5
1983 6
1984 3
1985 6
1986 13
1987 11
1988 8
1989 5
1990 4
1991 7
1992 5
1994 2
1995 3
1996 8
1997 4
1998 2
2000 2
2001 2
2002 2
2003 8
2004 9
2005 7
2006 7
2007 5
2008 3
2009 12
2010 5
2011 11
2012 15
2013 10
2014 11
2015 19
2016 26
2017 29
2018 29
2019 26
2020 40
2021 29
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

405 results
Results by year
Filters applied: . Clear all
Page 1
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Ramirez PT, et al. Among authors: buda a. N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31. N Engl J Med. 2018. PMID: 30380365 Clinical Trial.
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.
Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT. Obermair A, et al. Among authors: buda a. Am J Obstet Gynecol. 2020 Mar;222(3):249.e1-249.e10. doi: 10.1016/j.ajog.2019.09.036. Epub 2019 Oct 3. Am J Obstet Gynecol. 2020. PMID: 31586602 Free PMC article. Clinical Trial.
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.
Frumovitz M, Obermair A, Coleman RL, Pareja R, Lopez A, Ribero R, Isla D, Rendon G, Bernardini MQ, Buda A, Moretti-Marquez R, Zevallos A, Vieira MA, Zhu T, Land RP, Nicklin J, Asher R, Robledo KP, Gebski V, Ramirez PT. Frumovitz M, et al. Among authors: buda a. Lancet Oncol. 2020 Jun;21(6):851-860. doi: 10.1016/S1470-2045(20)30081-4. Lancet Oncol. 2020. PMID: 32502445 Clinical Trial.
Genetics--cellular basis.
Buda A, Pignatelli M. Buda A, et al. Br Med Bull. 2002;64:45-58. doi: 10.1093/bmb/64.1.45. Br Med Bull. 2002. PMID: 12421724 Review.
5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors.
Boutard N, Sabiniarz A, Czerwińska K, Jarosz M, Cierpich A, Kolasińska E, Wiklik K, Gluza K, Commandeur C, Buda A, Stasiowska A, Bobowska A, Galek M, Fabritius CH, Bugaj M, Palacz E, Mazan A, Zarębski A, Krawczyńska K, Żurawska M, Zawadzki P, Milik M, Węgrzyn P, Dobrzańska M, Brzózka K, Kowalczyk P. Boutard N, et al. Among authors: buda a. Bioorg Med Chem Lett. 2019 Feb 15;29(4):607-613. doi: 10.1016/j.bmcl.2018.12.051. Epub 2018 Dec 24. Bioorg Med Chem Lett. 2019. PMID: 30626559
405 results